Disease Description and Statistics Current State: Medicare Denial of Coverage Expert Opinion Clinical Studies Gap in Medical Care Cost to US

Similar documents
CLUSTER HEADACHE IS A STEREOtypical

Oxygen treatment for cluster headache attacks at different flow rates: a doubleblind, randomized, crossover study

Oxygen therapy for cluster headache. A mask comparison trial. A single-blinded, placebo-controlled, crossover study

Cluster headache (CH) is a type of primary headache

Miller S, Matharu MS. Managing patients with cluster headache in primary care

Trigeminal Autonomic Cephalalgias. Disclosures. Objectives 6/20/2018. Rashmi Halker Singh, MD FAHS UCNS Review Course June 2018

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

The Clinical Profile of Sumatriptan: Cluster Headache Key Words

Management of headache

Pause for thought. Dr Jane Anderson Consultant Neurologist

Treatment of Intractable Hemicrania Continua by Occipital Nerve Stimulation

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary

Clinical Commissioning Policy Statement: Sphenopalatine Ganglion Stimulation for Refractory Chronic Cluster Headache (Adults)

CLUS 42 PRACTICAL NEUROLOGY. Pract Neurol: first published as /j x on 1 October Downloaded from

Occipital Nerve Stimulation

ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา

ADVANCES IN MIGRAINE MANAGEMENT

Tears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE

Medical Policy. Description/Scope. Position Statement. Rationale

CLUSTER HEADACHES: THE WORST PAIN POSSIBLE? QUESTIONS:

...SELECTED ABSTRACTS...

Headache Master School Japan-Osaka 2016 II. Management of refractory headaches Case Presentation 2. SUNCT/SUNA: concept, management and prognosis

10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Disclosures. Objectives 6/2/2017

Management options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM

The best defense is a good offense. Optimizing the Acute Treatment of Migraine. Disclosures 11/10/2017

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)

Measure Components Numerator Statement

Occipital Nerve Stimulation with the Bion Microstimulator for the Treatment of Medically Refractory Chronic Cluster Headache

What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary

Get ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention

Original Policy Date

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Headache. Luke Bennetto Consultant Neurologist Engineers House 13 th September 2016

Zonisamide for migraine prophylaxis in refractory patients

Disclosures. Triptans for Kids 5/16/13

David W. Dodick M.D. Professor Director of Headache Medicine Department of Neurology Mayo Clinic Phoenix Arizona USA

See Important Reminder at the end of this policy for important regulatory and legal information.

MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache

Corporate Medical Policy

Migraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification

Setting The setting of the study was primary care. The economic study was conducted in the USA.

23 How Cluster Headache and Other Trigeminal Autonomic Cephalalgias Present

Chronic Daily Headaches

Adult with headache. Problem-specific video guides to diagnosing patients and helping them with management and prevention

VIEWS & REVIEWS Acute and preventive pharmacologic treatment of cluster headache

Anti-Migraine Agents

How do we treat migraine? New SIGN Guidelines

Stuart Weatherby Consultant Neurologist Derriford Hospital. Plymouth

Preventive treatment of migraine. Rebecca Burch, MD Brigham and Women s Faulkner Hospital Harvard Medical School Boston, MA

Does repeated subcutaneous administration of sumatriptan produce an unfavorable evolution in cluster headache?

Therapeutic Advances in Neurological Disorders

Overuse of barbiturate and opioid containing medications for primary headache disorders Description

Policy #: 411 Latest Review Date: January 2014

Current Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN

10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY

Clinical Characteristics of Chronic Daily Headache Patients Visit to University Hospital

Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention

Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, II. Management of Refractory Headaches

COMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS

Subject: CGRP Inhibitors

Calcitonin Gene Related Peptide Receptor Inhibitors Prior Authorization Criteria:

Trigeminal Autonomic. Trigeminal Autonomic Cephalalgias (TACs) María-Carmen Wilson,MD

Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine

Occipital Nerve Stimulation Corporate Medical Policy

Treatment Of Medication. Overuse Headache

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Despite the widespread use of triptans ... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability

Cluster and Other Nonmigraine Primary Headaches With Aurahead_1875. Randolph W. Evans, MD; Abouch V. Krymchantowski, MD, MSc, PhD, FAHS

Headache. Section 1. Migraine headache. Clinical presentation

ARxCH. Annual Review of Changes in Healthcare. Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines. Abstract

Cluster headache associated with acute maxillary sinusitis.

Outpatient Headache Care Guideline

Adult & Pediatric Patients. Stanford Health Care, Division Pain Medicine

Differentiating Migraine from Other Headache Types to Target Treatment Peter J. Goadsby, MD, PhD

ONZETRA XSAIL (sumatriptan) nasal powder

Headache: Using Neuromodulation as Therapy

Prevention and treatment of cluster headache

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline. Scottish intercollegiate Guidelines Network SIGN

Chronic cluster headache: a review

Subject: Aimovig (erenumab) Original Effective Date: 7/10/2018. Policy Number: MCP-320. Revision Date(s):

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.

Application of ICHD 2nd edition criteria for primary headaches with the aid of a computerised, structured medical record for the specialist

MIGRAINE ASSOCIATION OF IRELAND

SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection

Preventive Effect of Greater Occipital Nerve Block on Severity and Frequency of Migraine Headache

10/19/2018. Disclosures MIGRAINE PROPHYLAXIS. Objectives. Definitions Slide. What do you think the aooe stands for at the end of erenumab-aooe?

MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache

Mark W. Green, MD, FAAN

Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial

Sandler Family Trust. UCSF Medical Center. Headache A Review and Update. Headache The burden. Headache Group, UCSF Disclosure- by proportion*

Aleksandra Radojičić. Headache Center, Neurology Clinic, Clinical Center of Serbia

Is the Migraid device an asset in the non-pharmacologic treatment of migraine?

Migraine Controversies in Women s Health. Professor Peter J. Goadsby 5 December Department of Neurology

Goals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders

Zomig. Zomig / Zomig-ZMT (zolmitriptan) Description

Update on Diagnosis and Management of Migraines

Transcription:

Oxygen Therapy

Disease Description and Statistics Current State: Medicare Denial of Coverage Expert Opinion Clinical Studies Gap in Medical Care Cost to US Taxpayers Recommendations

Cluster headaches are characterized by an intense one-sided pain centered by the eye or temple. The pain lasts for one to two hours on average and may recur several times in a day The pain transcends by far the distress of the more common tension-type headache and even that of a migraine headache. Cluster headaches afflict less than 0.5% of the population Approximately 80% of cluster headaches are classified as episodic, affecting the patient for 2-3 months of the year; the remaining 20% are considered chronic with no reprieve. Source: 2016, http://medical-dictionary.thefreedictionary.com/cluster+headache

The NCD for the Home Use of Oxygen to Treat Cluster Headache (CH), released by CMS in January 2011, concludes that the currently available evidence does not demonstrate that the home use of oxygen to treat CH improves health outcomes among Medicare beneficiaries. Absent such evidence, CMS has concluded that additional clinical research is appropriate under Coverage with Evidence Development (CED). The NCD specifies that home use of oxygen to treat CH is covered for beneficiaries with CH participating in an approved prospective clinical study comparing normobaric 100% oxygen (NBOT) with at least one clinically appropriate comparator for the treatment of CH. Source: https://www.cms.gov/medicare/coverage/ There is, in fact, no patent protection or financial opportunity for any organization to undertake the proposed NCD study 100% of neurologists who specialize in headache disorders prescribe high-flow oxygen therapy as a firstline acute treatment

The standard treatment of acute attacks of cluster headache is inhalation of 100% oxygen. Cephalalgia. 1995 Oct;15 Suppl 15:33-6 Treatment of cluster headache: clinical trials Inhaled normobaric oxygen is an essential abortive treatment of cluster headache. Recognition of its efficacy for cluster headache goes back a half a century Trigeminal Autonomic Cephalalgias (M Matharu, Section Editor) Current Pain and Headache Reports April 2012, Volume 16, Issue 2, pp 175-179 A total of 109 patients treated 4 CH attacks with either oxygen (12 L/min) or inhaled air, given via a facial mask for 15 minutes. Oxygen was significantly superior to placebo with regards to the primary end point (elimination of pain or "adequate pain relief" at 15 minutes 78% vs 20%, with oxygen and air, respectively). As opposed to triptans, oxygen can be given to patients with a history of cardiovascular or cerebrovascular disease. Cluster Headache Acute and Prophylactic Therapy Avi Ashkenazi, MD; Todd Schwedt, MD Headache. 2011;51(2):272-286

Normobaric oxygen is an effective treatment of acute CH attacks in the majority of patients.it is well tolerated and has virtually no AEs. As opposed to triptans, there is no limitation to the number of times per day it can be used. A proper technique of use is crucial for good results with oxygen therapy. The patient should be instructed to use the oxygen via a nonrebreathable mask,at a rate of 7-10 L/min, in a sitting position, for at least 15-20 minutes. Patients may increase the flow rate up to 15 L/min if needed. The optimal flow rate should be determined individually for each patient. Cluster Headache Acute and Prophylactic Therapy Headache 2011;51:272-286 American Headache Society Avi Ashkenazi, MD; Todd Schwedt, MD

High-Flow Oxygen for Treatment of Cluster Headache: A Randomized Trial Anna S. Cohen, PhD, MRCP; Brian Burns, MD, MRCP; Peter J. Goadsby, MD, PhD, DSc, FRACP, FRCP Author Affiliations: Headache Group, Institute of Neurology, et. Al. JAMA. 2009;302(22):2451-2457. doi:10.1001/jama.2009.1855 Objective To ascertain whether high-flow inhaled oxygen was superior to placebo in the acute treatment of cluster headache. Design, Setting, and Patients A double-blind, randomized, placebo-controlled crossover trial of 109 adults (aged 18-70 years) with cluster headache as defined by the International Headache Society. Patients treated 4 headache episodes with high-flow inhaled oxygen or placebo, alternately. Patients were randomized to the order in which they received the active treatment or placebo. Patients were recruited and followed up between 2002 and 2007 at the National Hospital for Neurology and Neurosurgery, London, England. Intervention Inhaled oxygen at 100%, 12 L/min, delivered by face mask, for 15 minutes at the start of an attack of cluster headache or high-flow air placebo delivered alternately for 4 attacks. Main Outcome Measures The primary end point was to render the patient pain free, or in the absence of a diary to have adequate relief, at 15 minutes. Secondary end points included rendering the patient pain free at 30 minutes, reduction in pain up to 60 minutes, need for rescue medication 15 minutes after treatment, overall response to the treatment and overall functional disability, and effect on associated symptoms. Results Fifty-seven patients with episodic cluster headache and 19 with chronic cluster headache were available for the analysis. For the primary end point the difference between oxygen, 78% (95% confidence interval, 71%-85% for 150 attacks) and air, 20% (95% confidence interval, 14%-26%; for 148 attacks) was significant (Wald test, χ 2 5 = 66.7, P <.001). There were no important adverse events.

Extracranial vascular responses to sublingual nitroglycerin and oxygen inhalation in cluster headache patients. Headache. 1985;25:70-74. Drummond PD, Anthony M. Oxygen inhibits neuronal activation in the trigeminocervical complex after stimulation of trigeminal autonomic reflex,but not during direct dural activation of trigeminal afferents.headache.2009;49:11311143. Akerman S, Holland PR, Lasalandra MP, et al. Normobaric and hyperbaric oxygen therapy for migraine and cluster headache. Cochrane Database Syst Rev. 2008;3:CD005219. Bennett MH, French C, Schnabel A, et al. Response of cluster headache attacks to oxygen inhalation. Headache. 1981;21:1-4. Kudrow L. Treatment of cluster headache.a doubleblind comparison of oxygen v air inhalation. Arch Neurol. 1985;42:362-363. Fogan L. High oxygen flow rates for cluster headache. Neurology. 2004;63:593. Rozen TD. High-flow oxygen for treatment of cluster headache: A randomized trial. JAMA. 2009;302:2451-2457. 21. Cohen AS, Burns B, and Goadsby PJ. Treatment of a cluster headache patient in a hyperbaric chamber.headache. 1989;29:109-110. Weiss LD,Ramasastry SS,and Eidelman BH. Hyperbaric oxygen therapy in cluster headache. Pain. 1993; 52:243-245. Di Sabato F, Fusco BM, Pelaia P, et al. Hyperbaric oxygen treatment of active clusterheadache: A double-blind placebo-controlled cross-over study. Cephalalgia. 2002;22:730-739. Nilsson Remahl AI,Ansjon R,Lind F,et al.

Acute/abortive Sumatriptan succinate injection 6mg x 9/mo. Sumatriptan tablet (note: ineffective for CH due to duration of attack vs. route of administration) Preventive There are currently no approved preventive medications for CH Some off-label medications provide partial relief (verapamil, lithium, sodium valproate, gabapentin, topiramate, etc.)

Cluster patients average 3.5 severe attacks/day, 20 days/month Triptans are limited to 2 uses/day, 6/wk Medicare only allows 9 triptans/mo The average patient is left untreated for >40% of severe HA events every day, >90% in a month Patients with cardiovascular or cerebrovascular conditions are contraindicated for triptans Many patients resort to using welder s oxygen and/or selfmedicating Quality of Life is poor, many become disabled

Triptan cost: $639/mo meeting 10% of need vs. $200/mo. for home oxygen meeting 100% of need Disability cost: Median US income is $46,481 per year Average SSDI payment is $1166/mo ($13,992/yr) Results is a $32,489 economic loss per year per person

Based on healthcare expertise, clinical study evidence of efficacy and safety, and anecdotal evidence of an improved quality of life that reduces the incidence of disability, we strongly urge the CDC to reconsider its position on Medicare coverage for home high-flow oxygen for cluster headache